Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

Admilparant

Source date not recordedAnalyse record ↗

LPA1 antagonist in Phase 3 follow-up for idiopathic and progressive pulmonary fibrosis.

Modality
oral small-molecule lysophosphatidic acid receptor 1 antagonist
Availability (US)
Two Phase 3 ALOFT studies Active, not recruiting; long-term extension registered as Not yet recruiting
Biomarkers
forced vital capacity; spontaneous syncopal events; pulmonary-fibrosis progression; treatment-emergent adverse events
Hallmark targeted
extracellular-matrix remodeling, fibrosis, altered intercellular communication
Kind
investigational drug
Clinical trials
NCT06003426 — Phase 3 ALOFT-IPF, Active, not recruiting; NCT06025578 — Phase 3 ALOFT-PPF, Active, not recruiting; NCT07441408 — Phase 3 extension, Not yet recruiting